{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06311656",
            "orgStudyIdInfo": {
                "id": "18840"
            },
            "secondaryIdInfos": [
                {
                    "id": "J5C-MC-FOAA",
                    "type": "OTHER",
                    "domain": "DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"
                }
            ],
            "organization": {
                "fullName": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants",
            "officialTitle": "A Placebo-controlled, Phase 1, Participant- and Investigator-blinded, Single- and Multiple- Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-safety-tolerability-of-dc-in-healthy-asian-and-non-asian-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-22",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11-22",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-08",
            "studyFirstSubmitQcDate": "2024-03-08",
            "studyFirstPostDateStruct": {
                "date": "2024-03-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy asian participants and non-Asian participants. Part A consists of 2 groups and Part B, C, and D include optional groups.",
            "detailedDescription": "Part B and C added per protocol amendment (May 2024) Added Part B to explore higher dose levels and Part C to explore effects of food. Part D added per protocol amendment (June 2024) to explore higher multiple doses."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 77,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "LY4100511 (DC-853) Part A Fasted",
                    "type": "EXPERIMENTAL",
                    "description": "Single and multiple doses of LY4100511 (DC-853) administered orally.",
                    "interventionNames": [
                        "Drug: LY4100511 (DC-853)"
                    ]
                },
                {
                    "label": "LY4100511 (DC-853) Part B",
                    "type": "EXPERIMENTAL",
                    "description": "Single and multiple higher doses of LY4100511 (DC-853) administered orally.",
                    "interventionNames": [
                        "Drug: LY4100511 (DC-853)"
                    ]
                },
                {
                    "label": "LY4100511 (DC-853) Part C (Open Label)",
                    "type": "EXPERIMENTAL",
                    "description": "Single dose of LY4100511 (DC-853) administered orally in fed and fasted states.",
                    "interventionNames": [
                        "Drug: LY4100511 (DC-853)"
                    ]
                },
                {
                    "label": "LY4100511 (DC-853) Part D",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple higher doses of LY4100511 (DC-853) administered orally.",
                    "interventionNames": [
                        "Drug: LY4100511 (DC-853)"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo administered orally.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "LY4100511 (DC-853)",
                    "description": "Administered orally fasted",
                    "armGroupLabels": [
                        "LY4100511 (DC-853) Part A Fasted"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "LY4100511 (DC-853)",
                    "description": "Administered orally fasted.",
                    "armGroupLabels": [
                        "LY4100511 (DC-853) Part B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "LY4100511 (DC-853)",
                    "description": "Administered orally fed and fasted.",
                    "armGroupLabels": [
                        "LY4100511 (DC-853) Part C (Open Label)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "LY4100511 (DC-853)",
                    "description": "Administered orally fed and fasted.",
                    "armGroupLabels": [
                        "LY4100511 (DC-853) Part D"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Administered orally.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs)",
                    "description": "A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.",
                    "timeFrame": "Baseline up to 47 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY4100511 (DC-853)",
                    "timeFrame": "Predose up to 47 days"
                },
                {
                    "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4100511 (DC-853)",
                    "timeFrame": "Predose up to 47 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female participants who are overtly healthy as determined by medical history, vital signs, and physical examination.\n* Participants of Japanese, Chinese, and Non-Asian ethnicities\n* Have a body mass index within the range of 18.0 to 32 kilograms per square meter (kg/m\u00b2). For healthy Japanese participants, have a body mass index of 18.0 to 28.0 kg/m\u00b2\n* Have venous access sufficient to allow for blood sampling\n* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures\n\nExclusion Criteria:\n\n* Have a current or recent acute, active infection\n* Had any surgical procedure within 12 weeks prior to study\n* Are immunocompromised\n* Have presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or neuropsychiatric disorders or abnormal laboratory values\n* Are currently enrolled in a clinical study involving any experimental antibody or biologic therapy within the previous 6 months, or any other experimental therapy within 30 days before the first dose of the study intervention or during the study",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "This is a single site clinical trial 1-877-CTLILLY (1-877-285-4559) or",
                    "role": "CONTACT",
                    "phone": "1-317-615-4559",
                    "email": "ClinicalTrials.gov@lilly.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
                    "affiliation": "Eli Lilly and Company",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Altasciences Clinical Los Angeles, Inc",
                    "status": "RECRUITING",
                    "city": "Cypress",
                    "state": "California",
                    "zip": "90630",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.81696,
                        "lon": -118.03729
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}